期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms21010330
关键词
thyroid hormone receptor beta 1; subcellular localization; overall survival; breast cancer
资金
- University Paul Sabatier in Toulouse (France)
- China Scholarship Council (CSC) at the University of Munich [201606170096]
- Centre de Cooperation Universitaire Franco-Bavarois (CCUFB) [FK19-15]
The aim of this study was to investigate the expression of thyroid hormone receptor beta 1 (THR beta 1) by immunohistochemistry in breast cancer (BC) tissues and to correlate the results with clinico-biological parameters. In a well-characterized cohort of 274 primary BC patients, THR beta 1 was widely expressed with a predominant nuclear location, although cytoplasmic staining was also frequently observed. Both nuclear and cytoplasmic THR beta 1 were correlated with high-risk BC markers such as human epidermal growth factor receptor 2 (HER2), Ki67 (also known as MKI67), prominin-1 (CD133), and N-cadherin. Overall survival analysis demonstrated that cytoplasmic THR beta 1 was correlated with favourable survival (p = 0.015), whereas nuclear THR beta 1 had a statistically significant correlation with poor outcome (p = 0.038). Interestingly, in our cohort, nuclear and cytoplasmic THR beta 1 appeared to be independent markers either for poor (p = 0.0004) or for good (p = 0.048) prognosis, respectively. Altogether, these data indicate that the subcellular expression of THR beta 1 may play an important role in oncogenesis. Moreover, the expression of nuclear THR beta 1 is a negative outcome marker, which may help to identify high-risk BC subgroups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据